Interra Health’s platform now supports the U.S. Centers for Medicare and Medicaid Services’ GLP-1 Bridge program for people enrolled in Medicare Part D.
The initiative, which began July 1, allows eligible Part D beneficiaries to obtain GLP-1 medications for $50 per month. Interra’s system identifies patients who may qualify and alerts their healthcare providers during the prescribing process. It also guides clinicians through the necessary coding requirements and prior authorization procedures needed to access the benefit.
J.B. Powell, Chief Business Development Officer at Interra Health, said the platform had generated more than 170,000 prescribing alerts for over 30,000 individual prescribers since the program began. He noted that the program’s eligibility criteria and administrative requirements can be difficult for both clinicians and patients to navigate.
Powell said presenting the relevant information directly to providers while they are prescribing can streamline the process and give eligible Medicare beneficiaries a more straightforward route to obtaining GLP-1 drugs at a lower cost. Although the program remains in its early stages, he said Interra has been encouraged by its reach and by the opportunity to help clinicians identify a benefit that patients might otherwise not realize they could use.
Interra Health was created in March through the combination of DoseSpot and Arrive Health. The companies said the merged platform brings together Arrive Health’s coverage and pricing network with DoseSpot’s electronic prescribing technology.
According to Powell, the conventional prescribing process is often fragmented, creating extra administrative demands for clinicians while making it more difficult to determine the most economical treatment option for individual patients.
He said Interra’s differentiator is its ability to combine those functions within the prescribing workflow itself. For the GLP-1 Bridge program, for example, the platform can identify a potential cost-saving opportunity in real time, notify the prescriber during the medication-ordering process and provide the information needed to proceed, including details related to prior authorization.
Powell said Interra’s broader objective is to eliminate uncertainty from prescribing decisions. In his view, clinicians and patients should not have to independently determine whether a drug is covered, how much they will have to pay, whether a less expensive alternative exists or which administrative steps are necessary to obtain the medication.
Interra Health is focused on bringing greater transparency to what it describes as the “black box” surrounding prescription costs. Its platform integrates live affordability information, insurance coverage data and pharmacy options into the electronic prescribing workflow, giving clinicians cost-related information they can act on while treating patients. By surfacing those details before a prescription is completed, the company hopes to make it easier to compare medication choices, lower financial barriers and reduce the number of prescriptions that patients ultimately abandon because of cost.
The company’s leadership also changed as the new organization took shape. Josh Weiner, who previously served as CEO of DoseSpot, took the helm as Interra Health’s Chief Executive Officer. Kyle Kiser, formerly CEO of Arrive Health, transitioned to the board while taking on a senior advisory position.
Interra Health has become the newest supporter of the CMS GLP-1 Bridge Program, an initiative focused on improving patient access to important GLP-1 therapies. The program brings together healthcare organizations and stakeholders to explore ways of expanding affordability and availability for eligible patients.
By supporting the initiative, Interra Health is contributing to broader discussions around patient access, healthcare innovation, and the growing role of GLP-1 medicines in modern care. These therapies have attracted significant attention for their potential role in managing chronic health conditions and supporting better patient outcomes.The continued development of patient-focused programs demonstrates how healthcare stakeholders are responding to changing treatment demands. As new therapies and technologies enter the market, access initiatives may become an increasingly important part of the healthcare landscape.
